GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 14, 2023 16:16 ET
|
GeneDx Holdings Corp.
Financial results are in line with previously announced preliminary 2022 results; Reiterating 2023 guidance, including total revenue of $205-220 million Completed financing in January 2023...
GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference
March 01, 2023 07:30 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company...
GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
February 28, 2023 08:30 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Feb. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced its contributions to...
GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023
February 21, 2023 16:30 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release...
GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases
February 16, 2023 08:30 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Feb. 16, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, continues to...
GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering
January 31, 2023 16:15 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Jan. 31, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS) today announced the closing of its previously announced underwritten public offering of shares of its Class A...
GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery
January 30, 2023 08:30 ET
|
GeneDx Holdings Corp.
Company submitted nearly one quarter of all candidate gene submissions to GeneMatcher in 2022 and collaborated on 63 publications involving new disease-gene associations or expansion of phenotype...
GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering
January 27, 2023 06:00 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Jan. 27, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS) today announced the pricing of offerings for an aggregate of 428,571,429 shares of its Class A common stock at...
GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering
January 26, 2023 16:53 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Jan. 26, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it...
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
January 09, 2023 08:30 ET
|
GeneDx Holdings Corp.
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company’s common stock will trade on the Nasdaq under...